8 April 2009, London, UK: Cancer drug developer Antisoma plc (LSE:
ASM; USOTC: ATSMY) today announces that two Non-Executive Directors
of Antisoma have taken all or part of their fees for the quarter
ended 31 March 2009 in ordinary shares pursuant to resolutions of the
Board of Directors dated 14 September 2004 and subsequently.
The new ordinary shares were issued at a price of 26.5 pence per
share, this being the mid-market closing price on the last trading
day of the quarter (31 March 2009). The relevant Directors have
agreed not to dispose of the shares allotted for a minimum period of
The allotment and total holdings following this allotment are shown
Director Allotted Total Percentage of issued
8 April 2009 holding ordinary shares
Michael Pappas 14,151 887,184 0.14%
Michael Lewis 28,302 98,190 0.02%
Application will be made to the London Stock Exchange and the UK
Listing Authority for the admission of the new ordinary shares of 1p
each. The total number of ordinary shares in the Company in issue and
admitted to the Official List following the above allotments will be
The new ordinary shares will rank pari passu with the Company's
existing ordinary shares.
Alison Saville, Communications Executive
+44 (0)20 3249 2100
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company
that develops novel products for the treatment of cancer. The Company
has operations in the UK and the US. Please visit www.antisoma.com
for further information about Antisoma.
---END OF MESSAGE---
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.